Chair in Emerging Technologies 2021
The Stevens Group is very active in the development of bioengineering strategies for the biosensing and regenerative medicine fields. Prof Stevens aims to develop next generation biosensing technology platforms including a new MTAS (Multidimensional Target Agnostic Sensing) platform. Working closely with clinical and industrial partners, research will enable applications in point-of-care diagnostics, disease profiling and monitoring of biotech processes.
Professor Molly Morag Stevens
Related content
View all programmesChair in Emerging Technologies
This scheme aims to identify and provide long-term support to global research visionaries, developing emerging technolo…
Support for Research
The Academy runs a number of grants to support excellent researchers carry out engineering activities and to enable clo…